PriceTargets.com logo

Satsuma Pharmaceuticals - STSA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.10 As of 06/8/2023 09:00 PM ET
▼ -0.01 (-0.90%)
Get New Satsuma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STSA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Satsuma Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.10.

This chart shows the closing price for STSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Satsuma Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2023HC WainwrightDowngradeBuy ➝ NeutralLow
3/30/2023HC WainwrightReiterated RatingBuy$3.00Low
3/30/2023MizuhoReiterated RatingNeutral$2.00Low
11/17/2022LADENBURG THALM/SH SHLower Target$3.00Low
11/16/2022JonestradingDowngradeBuy ➝ HoldLow
11/15/2022HC WainwrightLower TargetBuy$18.00 ➝ $3.00Low
11/15/2022MizuhoDowngradeBuy ➝ Neutral$13.00 ➝ $2.00Low
11/15/2022SVB LeerinkDowngradeOutperform ➝ Market PerformLow
10/10/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$5.00 ➝ $15.00Low
9/21/2022HC WainwrightBoost TargetBuy$15.00 ➝ $18.00Low
8/31/2022LADENBURG THALM/SH SHInitiated CoverageBuy$16.00Low
8/24/2022JonestradingInitiated CoverageBuy$14.00Low
6/21/2022HC WainwrightReiterated RatingBuyLow
6/1/2022MizuhoReiterated RatingBuy$13.00High
5/13/2022MizuhoLower Target$15.00 ➝ $13.00Low
3/22/2022HC WainwrightReiterated RatingBuy$15.00High
11/14/2021SVB LeerinkReiterated RatingHold$5.00High
11/10/2021MizuhoReiterated RatingBuy$15.00High
6/22/2021MizuhoUpgradeNeutral ➝ Buy$7.00 ➝ $15.00High
6/20/2021SVB LeerinkReiterated RatingHoldLow
6/17/2021HC WainwrightReiterated RatingBuy$15.00High
5/12/2021SVB LeerinkBoost TargetMarket Perform$4.00 ➝ $5.00High
4/5/2021MizuhoBoost TargetPositive ➝ Neutral$3.50 ➝ $7.00Low
3/2/2021MizuhoReiterated RatingHold$3.50High
3/2/2021Credit Suisse GroupUpgradeUnderperform ➝ Neutral$6.50Medium
11/11/2020MizuhoLower TargetNeutral$4.00 ➝ $3.50Medium
9/21/2020HC WainwrightLower TargetBuy$35.00 ➝ $7.00Low
9/11/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$35.00 ➝ $4.00Medium
9/11/2020MizuhoDowngradeBuy ➝ Neutral$32.00 ➝ $4.00Low
9/11/2020Credit Suisse GroupDowngradeOutperform ➝ Underperform$33.00 ➝ $4.00Low
8/14/2020Credit Suisse GroupBoost TargetOutperform$32.00 ➝ $33.00High
7/27/2020HC WainwrightInitiated CoverageBuy$35.00Low
6/1/2020MizuhoReiterated RatingBuy$32.00Low
5/12/2020MizuhoReiterated RatingBuy$32.00High
5/6/2020MizuhoReiterated RatingBuy$32.00Medium
5/6/2020Credit Suisse GroupReiterated RatingBuy$32.00Medium
4/12/2020MizuhoReiterated RatingBuy$32.00High
3/11/2020SVB LeerinkBoost TargetOutperform$20.00 ➝ $35.00High
3/2/2020Credit Suisse GroupBoost Target$20.00 ➝ $32.00High
2/5/2020MizuhoInitiated CoverageBuyHigh
10/8/2019SVB LeerinkInitiated CoverageOutperform$20.00Low
10/8/2019Credit Suisse GroupInitiated CoverageOutperform$16.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Satsuma Pharmaceuticals logo
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.10
Low: $1.01
High: $1.14

50 Day Range

MA: $1.08
Low: $1.04
High: $1.11

52 Week Range

Now: $1.10
Low: $0.59
High: $8.08

Volume

1,829,700 shs

Average Volume

701,788 shs

Market Capitalization

$36.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Satsuma Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Satsuma Pharmaceuticals in the last twelve months:
View the latest analyst ratings for STSA.

What is the current price target for Satsuma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Satsuma Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Satsuma Pharmaceuticals in the next year.
View the latest price targets for STSA.

What is the current consensus analyst rating for Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for STSA.

What other companies compete with Satsuma Pharmaceuticals?

Other companies that are similar to Satsuma Pharmaceuticals include BriaCell Therapeutics, ProMIS Neurosciences, Cara Therapeutics, VYNE Therapeutics and ImmunoPrecise Antibodies. Learn More about companies similar to Satsuma Pharmaceuticals.

How do I contact Satsuma Pharmaceuticals' investor relations team?

Satsuma Pharmaceuticals' physical mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider's listed phone number is 650-410-3200 and its investor relations email address is [email protected]. The official website for Satsuma Pharmaceuticals is www.satsumarx.com. Learn More about contacing Satsuma Pharmaceuticals investor relations.